We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Moberg Pharma Ab (publ) | LSE:0P48 | London | Ordinary Share | SE0003613090 | MOBERG PHARMA ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 30.45 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
STOCKHOLM, April 27, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the divestment of the Balmex® brand to Randob Labs for a total consideration of $4.25 million plus the inventory value. The divestment results in a capital gain of circa $0.5 million.
The brand Balmex®, with a number of products for treating and preventing diaper rash, was acquired from Chattem Inc. in April, 2015. The role of Balmex® in the product portfolio has reduced after the 2016 acquisitions. Divesting the brand, enables Moberg Pharma to focus resources on its larger and more profitable brands. The brand generated net sales of $3.8 million in 2017.
Advisors
Hansen Law was engaged as legal advisor for the divestment of Balmex®.
About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on April 27th, 2018.
For additional information, please contact:
Peter Wolpert,
CEO,
telephone: +1-908-432-22-03
(US), +46-70-735-71-35
e-mail: peter.wolpert@mobergpharma.se
Anna Ljung,
CFO,
telephone: +46-707-66-60-30,
e-mail: anna.ljung@mobergpharma.se
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/moberg-pharma/r/moberg-pharma-completes-divestment-of-balmex--for--4-25-million,c2503137
The following files are available for download:
http://mb.cision.com/Main/1662/2503137/829415.pdf |
Moberg Pharma completes divestment of Balmex® for $4.25 million |
View original content:http://www.prnewswire.com/news-releases/moberg-pharma-completes-divestment-of-balmex-for-4-25-million-300637887.html
SOURCE Moberg Pharma
Copyright 2018 PR Newswire
1 Year Moberg Pharma Ab (publ) Chart |
1 Month Moberg Pharma Ab (publ) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions